GLP-1 receptor agonists & dual / triple agonists
GLP-1
Semaglutide
0.25 → 2.4 mg/wk
Weight management (Wegovy); T2D (Ozempic 0.25-2.0 mg)
GLP-1
Tirzepatide
2.5 → 15 mg/wk
Weight management (Zepbound); T2D (Mounjaro); OSA (Zepbound)
GLP-1
Wegovy (brand semaglutide)
0.25 → 2.4 mg/wk
Chronic weight management; CV risk reduction in obesity + CVD
GLP-1
Ozempic (brand semaglutide)
0.25 → 2.0 mg/wk
Type 2 diabetes; CV risk reduction in T2D + CVD
GLP-1
Zepbound (brand tirzepatide)
2.5 → 15 mg/wk
Chronic weight management; OSA in obesity
GLP-1
Mounjaro (brand tirzepatide)
2.5 → 15 mg/wk
Type 2 diabetes
GLP-1
Rybelsus (oral semaglutide)
3 → 14 mg/day
Type 2 diabetes (only)
GLP-1
Foundayo (orforglipron)
6 → 36 mg/day
Chronic weight management (March 2026)
GLP-1
Retatrutide (investigational)
2 → 12 mg/wk
Phase 3 obesity (TRIUMPH); not yet FDA-approved
GLP-1
Cagrilintide (investigational)
0.3 → 2.4 mg/wk
Long-acting amylin analog; co-formulation with sema (CagriSema) in trials
Research peptides & specialty compounds
Peptide
BPC-157
250-500 mcg twice daily
Tissue repair (research-only)
Peptide
GHK-Cu
1-2 mg topical or SC
Skin, collagen synthesis, copper peptide
Peptide
MOTS-c
5-10 mg/week
Mitochondrial peptide; metabolism, insulin sensitivity
Peptide
Sermorelin
200-300 mcg/day
GHRH analog; endogenous growth hormone
Peptide
CJC-1295 / Ipamorelin
100-200 mcg each, 2-3×/day
GHRH + ghrelin agonist combo; growth hormone secretagogue
Peptide
Tesamorelin (FDA-approved)
2 mg/day
HIV-associated lipodystrophy (FDA approved 2010); visceral fat
Peptide
MK-677 (ibutamoren)
10-25 mg/day
Oral ghrelin mimetic; GH/IGF-1 elevation
Peptide
5-Amino-1MQ
50-150 mg/day
NNMT inhibitor; metabolic & adipose research compound
Peptide
PT-141 (bremelanotide)
0.5-2 mg PRN
Sexual desire/arousal (FDA approved as Vyleesi 2019)
Peptide
Kisspeptin
50-200 nmol/kg
GnRH stimulation; reproductive endocrinology research
Peptide
Glutathione (GSH)
200-600 mg IV / 2 g IM
Antioxidant; skin lightening (off-label); detox protocols
Peptide
Thymosin Alpha-1
1.6 mg twice weekly
Immune modulator (T-cell activation)
Peptide
Selank
500 mcg-1 mg/day intranasal
Anxiolytic, cognitive enhancement (Russia approved)
Peptide
KPV (Lys-Pro-Val)
200-500 mcg/day
Anti-inflammatory tripeptide; gut and skin inflammation
Peptide
Enclomiphene
12.5-25 mg/day
SERM; secondary hypogonadism; trans estrogen blockade
Peptide
GLOW protocol (GHK-Cu + BPC-157 + TB-500)
Stack protocol
Combined skin + repair stack
Peptide
SS-31 (elamipretide)
40 mg/day SC
Mitochondrial; cardiolipin-targeting (Phase 3 BARTH/PMD)
Peptide
FOXO4-DRI
Research protocols only
Senolytic (research compound); not FDA-approved
Considering GLP-1 telehealth?
Our current Editor's Pick is NexLife for both compounded semaglutide ($145/mo on 12-month plan) and compounded tirzepatide ($186/mo on 12-month plan) — flat-rate across the full titration ladder, MD/DO oversight, Care360 coaching included. Read the full NexLife review →